Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Kingsoft Cloud Holdings Limited (KC) vs Eli Lilly And Co (LLY) Price & Performance

Kingsoft Cloud Holdings LimitedTrade
Eli Lilly And CoTrade

Price performance (Past 24H)

Key statistics

Kingsoft Cloud Holdings Limited vs Eli Lilly And Co — how do they compare? Kingsoft Cloud Holdings Limited trades at $11.74 (market cap $3.53B), while Eli Lilly And Co trades at $1,214.23 (market cap $1.10T). The key difference: Eli Lilly And Co is far larger — about 311.6× Kingsoft Cloud Holdings Limited's market cap, and Eli Lilly And Co pays a 0.56% dividend while Kingsoft Cloud Holdings Limited pays none. Which is the better fit depends on your goals.

KCLLY
Market Cap
$3.53B$1.10T
Sector
TechnologyHealth
52-Week High
$18.21$1.24K
52-Week Low
$8.58$639.43
Enterprise Value
$3.84B$1.14T
Dividend Yield
0.56%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Kingsoft Cloud Holdings Limited

Kingsoft Cloud (KC) trades at $12.33, up 1.48% with a bullish technical signal despite negative profitability. The company shows strong revenue growth momentum with Q1 2026 revenue increasing 37% year-over-year, though net margins remain negative at -9.39%. Recent analyst coverage is overwhelmingly positive with 70% buy ratings, driven by AI cloud growth where AI now represents over half of public cloud revenue.

The outlook remains cautiously optimistic as KC trades at attractive valuations (P/S 2.26x) with significant AI-driven growth potential, but investors face execution risks from heavy capital expenditures and persistent profitability challenges. The upcoming Q2 2026 earnings report on August 19 will be critical for validating the AI growth narrative.

Eli Lilly And Co

Eli Lilly (LLY) trades at $1,185.71, down 0.59% on the day, with a bullish technical signal from moving averages and strong fundamental momentum. The company reported Q2 2026 revenue growth of 48% to $23 billion, beating estimates, driven by demand for Mounjaro and Zepbound. Valuation ratios like P/E of 39.8 and P/S of 13.34 reflect high growth expectations, while profitability remains robust with a net income margin of 33.53%.

Outlook is positive due to pipeline advancements like retatrutide and raised 2026 guidance, but risks include competitive pressures and regulatory scrutiny. Analysts are bullish with a consensus price target of $1,380, citing sustained double-digit growth and market leadership in weight-loss drugs as key drivers for upside.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Kingsoft Cloud Holdings Limited

Kingsoft Cloud is a leading independent cloud service provider in China. It offers a comprehensive suite of cloud products and solutions tailored for industries like gaming, video streaming, and financial services.

Read more on KC

About Eli Lilly And Co

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer

Read more on LLY